In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including:

• Mechanistic differences between CELMoDs and IMiDs
• Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
• The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/3IwbslQ

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:

• Key Comorbidities in Patients with HR+/HER2- MBC
• Impact of Polypharmacy
• Role of APPs in Comprehensive Care
• Role of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBC
• Utility of RWE data
• Communicating Treatment Options With Patients and Caregivers
• Understanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life

Link to full program:
https://bit.ly/4jCQe38

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.

• Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCs
• On-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicity
• Combination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns
  

Presenters:

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above.